IRVING, Texas, June 17, 2025 /PRNewswire/ — Caris Life Sciences® (Caris), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced the pricing of its initial public offering of 23,529,412 shares of […]
IRVING, Texas, May 23, 2025 /PRNewswire/ — Caris Life Sciences® (“Caris”), a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, today announced that it has filed a registration statement on Form S-1 with the […]
Caris Life Sciences and the Caris POA collaborators will collectively present 37 abstracts IRVING, Texas, May 22, 2025 /PRNewswire/ — Caris Life Sciences® (Caris), a leading next-generation AI TechBio company and precision medicine pioneer, today announced […]
IRVING, Texas, May 12, 2025 /PRNewswire/ — Caris Life Sciences®(Caris), a leading next-generation AI TechBio company and precision medicine pioneer, performs MET Immunohistochemistry (IHC) testing as standard of care for all non-squamous non-small cell lung […]
Title: Real-World Study Shows Variable Efficacy of Tissue-Agnostic Drugs in Cancer Treatment A recent study conducted on over 295,000 patients has shed light on the varying effectiveness of tissue-agnostic drugs in treating different types of […]
